Antwerp’s Koios Care lands €1M to scale its AI platform for Parkinson’s monitoring and care

Antwerp-based Koios Care has secured €1M in seed funding led by Evercurious VC to advance its AI-powered platform for Parkinson’s disease monitoring and care.

Founded by Dr. Konstantinos Kyritsis and Dr. Dimitris Iakovakis in 2022, the health tech startup transforms passive data from everyday smartphones and smartwatches into actionable clinical insights.

The funding will support crucial steps in regulatory clearance, market commercialisation, and ongoing evidence generation. Koios Care plans to expand its digital health tool “Parkiwatch” throughout EU neurological clinics while building key partnerships with industry and pharmaceutical companies.

The round was led by the Greek early-stage deeptech fund Evercurious VC, with strong participation from Astylab Ventures, imec.istart fund and several private angel investors, coordinated by HeBAN.

Koios Care is in use by research institutions, industry partners, and hospital pilot programmes. The company’s latest study included 130 patients across numerous clinics in the European Union.

Addressing the “silent pandemic” affecting 10 million globally

Parkinson’s Disease represents the fastest-growing neurological disorder globally, now affecting over 10 million people and increasingly described as a “silent pandemic” by the medical community.

Koios Care’s platform bridges the gap between patients’ daily lives and clinical care by delivering clinically meaningful insights through everyday devices, effectively accelerating time-to-market for new therapies in neuroscience.

The company’s approach aligns with current regulatory guidance on digital health technologies and aims to improve drug trial success rates by delivering sensitive, clinically meaningful endpoints rooted in patients’ daily functioning.

From clinical research to real-world patient impact

Dr. Kyritsis brings extensive experience in digital health and neurological condition monitoring, while Dr. Iakovakis contributes deep technical expertise in AI and digital biomarkers.

Dr. Konstantinos Kyritsis, co-founder and CEO of Koios Care, says, “There’s a significant gap between what people with Parkinson’s truly need and what they currently receive. It’s not just about managing symptoms, it’s about meaningfully improving their overall Quality of Life. That’s the gap Koios Care is here to close.”

“One patient using the technology to clearly communicate with their neurologist told us, ‘Sometimes, on my current medication scheme, it feels like I have no Parkinson’s.’ That’s not just encouraging, it’s a powerful glimpse of what’s possible.”

Alex Vamvakas, partner at Evercurious VC, adds, “Koios Care’s innovative approach to passively monitoring Quality of Life with everyday devices is a game-changer for neurodegenerative disorders. We are impressed by the team’s scientific rigor, the clinical validation and the vision to reshape long-term neurodegenerative conditions’ care and enable the shift toward personalised, data-driven disease management at scale.”

Evercurious VC is an Athens-based VC firm founded by engineers turned investors, focusing on European early-stage deeptech companies developing defensible technologies to tackle global challenges.

Dual business model

Koios Care operates a dual business model serving both patients and industry. For patients and care providers, it offers a digital health tool supporting quality of life and driving outcomes; for pharmaceutical and medical device companies, it serves as a powerful R&D platform enabling real-world evidence generation and precision in therapeutic development.

Looking ahead, the company plans to develop drug-device combination products and extend its technology to tackle conditions including Mild Cognitive Impairment, Alzheimer’s, narcolepsy, and eating disorders.

Dr. Dimitris Iakovakis, co-founder and CTO of Koios Care, says, “For too long, patients, clinicians and researchers have lacked continuous, objective data to truly personalise Parkinson’s care and understand the real-life impact of the disease and its treatments. This funding reflects the urgent need for a new standard in care.”

“With our solution, we empower patients to better understand their condition, equip medical teams with unprecedented insights, and provide pharmaceutical companies with a powerful tool to accelerate the development of more effective therapies.”